DelveInsight’s, “Chronic Spontaneous Urticaria Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the Chronic Spontaneous Urticaria pipeline drug profiles, including Chronic Spontaneous Urticaria clinical trials and nonclinical stage products. It also covers the Chronic Spontaneous Urticaria therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Spontaneous Urticaria Pipeline Report

 

• Over 20+ Chronic Spontaneous Urticaria companies are evaluating 20+ Chronic Spontaneous Urticaria pipeline therapies in various stages of development, and their anticipated acceptance in the Chronic Spontaneous Urticaria market would significantly increase market revenue.

 

• The leading Chronic Spontaneous Urticaria Companies include United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, and others

 

• Promising Chronic Spontaneous Urticaria Pipeline Therapies include UB-221, GBR 310, Ligelizumab, UCB8600, Antolimab, Dupilumab, GI-301, CDX-0159, LY3454738, and others.

 

• The Chronic Spontaneous Urticaria companies and academics are working to assess challenges and seek opportunities that could influence Chronic Spontaneous Urticaria R&D. The Chronic Spontaneous Urticaria therapies under development are focused on novel approaches to treat/improve Chronic Spontaneous Urticaria.

 

Request a sample and discover the recent breakthroughs happening in the Chronic Spontaneous Urticaria Pipeline landscape @ Chronic Spontaneous Urticaria Pipeline Outlook Report

 

Chronic Spontaneous Urticaria Overview

Urticaria (also called hives, wheals, or nettle rash) is characterized by pruritic, erythematous, and edematous wheals. Chronic Spontaneous Urticaria (CSU) is defined as hives that are present for at least or greater than 6 weeks and for the most days of the week. Chronic spontaneous urticaria is characterized by the presence of weals and angioedema.

 

Recent Developmental Activities in the Chronic Spontaneous Urticaria Treatment Landscape

 

• Celltrion has initiated the clinical trials of its CT-P39, a biosimilar of omalizumab (Xolair), to Phase 3 trials in November 2020.

 

• United BioPharma obtained Taiwan FDA approval for conducting a phase I clinical trial of its UB21 product, a third-generation monoclonal anti-IgE antibody and initiated a phase I clinical trial in May 2020.

 

• The U.S. Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of Chronic Spontaneous Urticaria (CSU) in patients who have an inadequate response to H1-antihistamine treatment.

 

• Tezepelumab is a human monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being developed and investigated for the treatment of Chronic Spontaneous Urticaria (CSU) by Amgen in collaboration with AstraZeneca.

 

• Celldex Therapeutics has initiated Phase 1b studies of CDX-0159 in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CINDU), both mast cell-related diseases, in the fall of 2020.

 

• Lirentelimab (AK002) being developed by Allakos, targets Siglec-8, an inhibitory receptor found on the surface of mast cells and eosinophils. Allakos has completed an open-label Phase 2a clinical trial evaluating lirentelimab in patients with multiple forms of Chronic Urticaria.

 

For further information, refer to the detailed Chronic Spontaneous Urticaria Drugs Launch, Chronic Spontaneous Urticaria Developmental Activities, and Chronic Spontaneous Urticaria News, click here for Chronic Spontaneous Urticaria Ongoing Clinical Trial Analysis

 

Chronic Spontaneous Urticaria Emerging Drugs Profile

 

Dupilumab: Sanofi

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation. Dupixent is approved for use in certain patients with atopic dermatitis, asthma, CRSwNP or EoE in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including chronic spontaneous urticaria, which is in the preregistration developmental stage.

 

Tezepelumab: Amgen

Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP). The drug is in Preregistration for Asthma treatment; in Phase III for rhinosinusitis; in Phase II clinical studies for the treatment of chronic urticarial and chronic obstructive pulmonary disease. Tezepelumab is being developed in collaboration with AstraZeneca.

 

Barzolvolimab: Celldex Therapeutics

Barzolvolimab (CDX-0159) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival, and activity of mast cells. In certain inflammatory diseases, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is being evaluated in the Phase II development stage for the treatment of chronic spontaneous urticaria.

 

Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Chronic Spontaneous Urticaria. The companies which have their Chronic Spontaneous Urticaria drug candidates in the most advanced stage, i.e. preregistration, Sanofi.

 

Find out more about the Chronic Spontaneous Urticaria Diagnosis and Treatment of patients @ Chronic Spontaneous Urticaria Ongoing Clinical Trials Analysis

 

Scope of the Chronic Spontaneous Urticaria Pipeline Report

 

• Coverage- Global

 

• Chronic Spontaneous Urticaria Companies- United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, and others

 

• Chronic Spontaneous Urticaria Pipeline Therapies- UB-221, GBR 310, Ligelizumab, UCB8600, Antolimab, Dupilumab, GI-301, CDX-0159, LY3454738, and others.

 

• Chronic Spontaneous Urticaria Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Discover more about the list of FDA-approved drugs for Chronic Spontaneous Urticaria @ Chronic Spontaneous Urticaria Treatment Landscape

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Spontaneous Urticaria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Spontaneous Urticaria– DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Dupilumab: Sanofi
9. Drug profiles in the detailed report…..
10. Late Stage Products (Phase III)
11. Remibrutinib: Novartis
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. Tezepelumab: Amgen
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug: Company
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Briquilimab: Jasper Therapeutics
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Chronic Spontaneous Urticaria Key Companies
24. Chronic Spontaneous Urticaria Key Products
25. Chronic Spontaneous Urticaria- Unmet Needs
26. Chronic Spontaneous Urticaria- Market Drivers and Barriers
27. Chronic Spontaneous Urticaria- Future Perspectives and Conclusion
28. Chronic Spontaneous Urticaria Analyst Views
29. Chronic Spontaneous Urticaria Key Companies
30. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/